Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF-1

International Journal of Cancer

Volumn 74, Issue 6, 1997, Pages 571-575

  Chambers, Setsuko K ^a   Ivins, Christina M ^a   Carcangiu, Maria L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; TUMOR CELLS, CULTURED;

EID: 0031456810     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971219)74:6<571::AID-IJC2>3.0.CO;2-R     Document Type: Article

References (23)

1. BACUS, S., FLOWERS, J.L., PRESS, M.F., BACUS, J.W. and MCCARTY, K.S., JR. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Amer. J. clin. Pathol., 90, 233-239 (1988).
2. BOUCHET, C., SPYRATOS, F., MARTIN, P.M., HACÉNE, K., GENTILE, A. and OGLOBINE, J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Brit. J. Cancer, 69, 398-405 (1994).
3. CHAMBERS, S.K., GERTZ, R.E., IVINS, C.M. and KACINSKI, B.M. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer, 75, 1627-1633 (1995a).
4. CHAMBERS, S.K. and KACINSKI, B.M. Messenger RNA decay of macrophage colony-stimulating factor in human ovarian carcinomas in vitro. J. Soc. gynecol. Invest., 1, 310-316 (1994).
5. CHAMBERS, S.K., KACINSKI, B.M., IVINS, C.M. and CARCANGIU, M.L. Overexpression of epithelial CSF-1 and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer; contrasted to a protective effect of stromal CSF-1. Clin. Cancer Res., 3, 999-1007 (1997).
6. CHAMBERS, S.K., WANG, Y., GERTZ, R.E. and KACINSKI, B.M. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res., 55, 1578-1585 (1995b).
7. FOEKENS, J.A., BUESSECKER, F., PETERS, H.A., KRAINICK, U., VAN PUTTEN, W.L.J., LOOK, M.P., KLIJN, J.G.M. and KRAMER, M.D. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res., 55, 1423-1427 (1995).
8. GANESH, S., SIER, C.F.M., GRIFFIOEN, G., VLOEDGRAVEN, H.J.M., DE BOER, A., WELVAART, K., VAN DE VELDE, C.J.H., VAN KRIEKEN, J.H.J.M., VERHEIJEN, J.H., LAMERS, C.B.H.W. and VERSPAGET, H.W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54, 4065-4071 (1994).
9. KACINSKI, B.M., CARTER, D., MITTAL, K., YEE, L.D., SCATA, K.A., D'ONOFRIO, L., CHAMBERS, S.K., WANG, K., YANG-FENG, T., ROHRSCHNEIDER, L.R. and ROTHWELL, V.M. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Amer. J. Pathol., 137, 135-147 (1990).
10. KACINSKI, B.M., SCATA, K.A., CARTER, D., YEE, L.D., SAPI, E., KING, B.L., CHAMBERS, S.K., JONES, M.A., PIRRO, M.H., STANLEY, E.R. and ROHRSCHNEIDER, L.R. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene, 6, 941-952 (1991).
11. KACINSKI, B.M., STANLEY, E.R., CARTER, D., CHAMBERS, J.T., CHAMBERS, S.K., KOHORN, E.I. and SCHWARTZ, P.E. Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int. J. Rad. Oncol. Biol. Phys., 17, 159-164 (1984).
12. KUHN, W., PACHE, L., SCHMALFELDT, B., DETTMAR, P., SCHMITT, M., JANICKE, F. and GRAEFF, H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol., 55, 401-409 (1994).
13. LAUG, W.E., CAO, X.R., Yu, Y.B., SHIMADA, H. and KRUITHOF, E.K.O. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res., 53, 6051-6057 (1993).
14. MUELLER, B.M., Yu, Y.B. and LAUG, W.E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. nat. Acad. Sci. (Wash.), 92, 205-209 (1995).
15. OKEN, M.M., CREECH, R.H., TORMEY, D.C., HORTON, J., DAVIS, T.E., MCFADDEN, E.T. and CARBONE, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Amer. J. clin. Oncol. (CCT), 5, 649-655 (1982).
16. PRICE, F.V., CHAMBERS, S.K., CHAMBERS, J.T., CARCANGIU, M.L., SCHWARTZ, P.E., KOHORN, E.I., STANLEY, E.R. and KACINSKI, B.M. CSF-1 concentration in primary ascites of ovarian cancer is a significant predictor of survival. Amer. J. Obstet. Gynecol. 168, 520-527 (1993).
17. PUJADE-LAURAINE, E., Lu, H., MIRSHAHI, S., SORIA, J., SORIA, C., BERNADOU, A., KRUITHOF, E.K.O., LIJNEN, H.R. and BURTIN, P. The plasminogen-activation system in ovarian tumors. Int. J. Cancer, 55, 27-31 (1993).
18. RAMAKRISHNAN, S., Xu, F.J., BRANDT, S.J., NEIDEL, I.E., BAST, R.C. and BROWN, E.L. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J. clin. Invest., 83, 921-926 (1989).
19. SCHMALFELDT, B., KUHN, W., REUNING, U., PACHE, L., DETTMAR, P., SCHMITT, M., JANICKE, F., HÖFLER, H. and GRAEFF, H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res., 55, 3958-3963 (1995).
20. SCHOLL, S., BASCOU, C.H., MOSSERI, V., OLIVARES, R., MAGDELENAT, H., DORVAL, T., PALANGI, T., VALIDARE, P., POUILLART, P. and STANLEY, E.R. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Brit. J. Cancer, 62, 342-346 (1994).
21. SHINKFIELD, M.N.F., BURNAND, K.G., BALLANCE, D.J., ZITKA, M. and EASTHAM, D. The effect of recombinant plasminogen activator inhibitor-2 (PAI-2) on the growth of a human tumour cell line in-vitro and in-vivo. Fibrinolysis, 6, 59-63 (1992).
22. TAKEUCHI, Y., NAKAO, A., HARADA, A., NONAMI, T., FUKATSU, T. and TAKAGI, H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemicul study. Amer. J. Gastroenterol., 88, 1928-1933 (1993).
23. ZOU, Z., ANISOWICZ, A., HENDRIX, M.J.C., THOR, A., NEVEU, M., SHENG, S., RAFIDI, K., SEFTOR, E. and SAGER, R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263, 526-529 (1994).